Market Overview

Tetraphase Pharmaceuticals to Host First Quarter 2019 Financial Results Conference Call

Share:

Tetraphase
Pharmaceuticals, Inc.
(NASDAQ:TTPH), a biopharmaceutical company
focused on developing and commercializing novel tetracyclines to treat
serious and life-threatening conditions, today announced that company
management will host a conference call at 4:30 p.m. ET on Wednesday, May
8, 2019 to discuss the Company's first quarter 2019 financial results
and provide a general corporate update.

The conference call may be accessed by dialing 844-831-4023 (U.S. and
Canada) or 731-256-5215 (international) and entering conference ID
number 2794213. A live audio webcast of the conference call will be
available online from the "Investors – Events & Presentations" section
of the Tetraphase website at www.tphase.com.

A replay of the conference call will be available from 7:30 p.m. ET on
Wednesday, May 8, 2019, through 7:30 p.m. ET on Wednesday, May 15, 2019
by dialing 855-859-2056 (U.S. and Canada) and 404-537-3406 for
(international) callers. The conference ID number is 2794213. A replay
of the webcast will be available by visiting Tetraphase's website.

About Tetraphase Pharmaceuticals, Inc.

Tetraphase Pharmaceuticals, Inc., is a biopharmaceutical company using
its proprietary chemistry technology to create novel tetracyclines for
serious and life-threatening conditions, including infections caused by
many of the multidrug-resistant bacteria highlighted as urgent public
health threats by the World Health Organization and the Centers for
Disease Control and Prevention. The Company has created more than 3,000
novel tetracycline compounds using its proprietary technology platform.
Tetraphase's lead product, XERAVA™, is approved for the treatment of
complicated intra-abdominal infections by the U.S. Food and Drug
Administration and the European Medicines Agency. The Company's pipeline
also includes TP-271 and TP-6076, which are in Phase 1 clinical trials,
and TP-2846, which is in preclinical testing for acute myeloid leukemia.
Please visit www.tphase.com
for more company information.

View Comments and Join the Discussion!
 
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com